Guerbet
19.77
11-April-25 10:29:25
15 minutes delayed
Stocks
-0.33
-1.64%
Today's range
19.60 - 20.15
ISIN
FR0000032526
Source
Cboe
-
22 Mar 2023 11:45:58 By Nasdaq GlobeNewswire
-
09 Feb 2023 10:46:34 By Nasdaq GlobeNewswire
-
Guerbet: 2023 Strategic Priorities
16 Jan 2023 11:40:42 By Nasdaq GlobeNewswire
-
11 Jan 2023 12:46:47 By Nasdaq GlobeNewswire
-
Guerbet: Guerbet announces a change in governance for its Artificial Intelligence projects
03 Nov 2022 12:04:18 By Nasdaq GlobeNewswire
-
Guerbet: Revenue at September 30, 2022
20 Oct 2022 10:45:00 By Nasdaq GlobeNewswire
-
Guerbet announces U.S. Food and Drug Administration (FDA) approval of Elucirem™ (Gadopiclenol)
21 Sep 2022 12:00:00 By Nasdaq GlobeNewswire
-
Guerbet: 2022 half-year results
21 Sep 2022 10:45:00 By Nasdaq GlobeNewswire
-
Guerbet: Revenue at June 30, 2022
21 Jul 2022 10:45:00 By Nasdaq GlobeNewswire
-
Guerbet receives EMA acceptance of EluciremTM as the Brand Name for Gadopiclenol
13 Jun 2022 01:30:00 By Nasdaq GlobeNewswire
-
21 Apr 2022 10:45:00 By Nasdaq GlobeNewswire
-
06 Apr 2022 01:30:00 By Nasdaq GlobeNewswire
-
29 Mar 2022 11:05:55 By Nasdaq GlobeNewswire
-
23 Mar 2022 11:45:00 By Nasdaq GlobeNewswire
-
07 Mar 2022 11:00:48 By Nasdaq GlobeNewswire
-
10 Feb 2022 10:54:31 By Nasdaq GlobeNewswire
-
04 Jan 2022 11:02:01 By Nasdaq GlobeNewswire
-
Guerbet and Bracco Imaging Announce a Global Strategic Collaboration Agreement for Gadopiclenol
14 Dec 2021 00:00:00 By Nasdaq GlobeNewswire
-
Guerbet: Revenue at September 30, 2021
21 Oct 2021 10:46:04 By Nasdaq GlobeNewswire